HYUNDAI BIOLAND Co.,Ltd.: debt-to-equity, ROE and more
KOSDAQ, Legal name HYUNDAI BIOLAND Co.,Ltd.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 22.6%
- Equity ratio
- 81.6%
- ROE
- 0.2%
- Op. margin
- 9.7%
- Rev. growth
- 9.2%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩70 | 831.2% |
| 2024 | ₩70 | 36.8% |
| 2023 | ₩70 | 13.0% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 37.8% | 72.6% | -9.3% | 10.4% | n/a |
| FY2022 consolidated | 36.2% | 73.4% | 3.7% | 9.1% | -3.5% |
| FY2023 consolidated | 35.4% | 73.9% | 5.9% | 7.0% | 2.6% |
| FY2024 consolidated | 41.1% | 70.9% | 4.1% | 13.7% | 17.5% |
| FY2025 consolidated | 22.6% | 81.6% | 0.2% | 9.7% | 9.2% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩102.8B | ₩99.2B | ₩101.7B | ₩119.5B | ₩130.5B |
| Operating profit | ₩10.7B | ₩9.1B | ₩7.1B | ₩16.4B | ₩12.7B |
| Pre-tax income | -₩15.2B | ₩6.8B | ₩10.0B | ₩15.9B | ₩12.3B |
| Net income | -₩11.7B | ₩4.8B | ₩8.1B | ₩5.7B | ₩252.6M |
| Total assets | ₩172.7B | ₩176.1B | ₩184.1B | ₩194.7B | ₩166.9B |
| Total liabilities | ₩47.4B | ₩46.8B | ₩48.1B | ₩56.7B | ₩30.7B |
| Total equity | ₩125.3B | ₩129.3B | ₩136.0B | ₩138.0B | ₩136.1B |
| Paid-in capital | ₩7.5B | ₩7.5B | ₩7.5B | ₩15.0B | ₩15.0B |
| Debt/equity (source value) | 37.8% | 36.2% | 35.4% | 41.1% | 22.6% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1995-09-01
- Listed
- 01/05/17
- Employees
- 342
- Auditor
- 한영회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101111192981
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 현대바이오랜드Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.